

Supplementary materials




Fig. S1. The secretion of IL-2 and IL-4 after intravenous administration of samples. (A) The IL-2 level (upper) and IL-4 level (lower) measured on the 3rd days after administration process. (B) The IL-2 level (upper) and IL-4 level (lower) measured on the 6th days after administration process. Values are the mean \pm SD (n = 3, **P <0.01).




Fig. S2. Relative populations of macrophages (CD14⁺ cells) in spleens at day 7 after twice systemic administrations of samples




Fig. S3. Body weight variations of mice during the process of administration.




Fig. S4. Kaplan-Meier survival curve of intracranial B16F10 melanoma bearing mice treated with different formulations (n= 7).




Fig. S5. The cytotoxicity study of PTX-TH-Lip and PTX/αGC-TH-Lip, and PTX-TH-Lip plus IFN-γ against B16F10 cells after 24h incubation.




Fig. S6. HE staining of organs after different treatments. Scale bars represent 100 μ m.




Fig. S7. The Cytotoxicity Assay of CD8⁺ T lymphocytes against C6 cells and A549 cells. (A) The cell lysis of C6 cells after 6h incubation with B16F10-stimulated CD8⁺ T cells. (B) The cell lysis of A549 cells after 6h incubation with B16F10-stimulated CD8⁺ T cells. “E/T ratio” represents effector/target cell ratio. (n = 3, mean \pm SD).